Literature DB >> 9914547

Clinical-severity staging system for oral cavity cancer: five-year survival rates.

F A Pugliano1, J F Piccirillo, M R Zequeira, J M Fredrickson, C A Perez, J R Simpson.   

Abstract

The objective of this research is to improve the classification and survival estimates for patients with oral cavity cancer by combining cancer symptom severity and comorbidity with the current TNM staging system. The study design is a retrospective medical record review that uses explicit coding criteria. The medical records of 277 patients receiving initial treatment at the Washington University Medical Center between 1980 and 1989 were reviewed. Multivariate analysis identified patient factors that significantly affected 5-year survival. These patient factors, symptom severity and comorbidity, were combined with TNM to create a composite clinical-severity staging system. The overall 5-year survival rate was 46% (128/277). Survival rates by TNM stage were as follows: stage I, 72% (36/50); II, 54% (45/84); III, 37% (24/65); and IV, 29% (23/78) (chi2 = 25.27, P = 0.001). When patients were grouped according to the clinical-severity staging system, survival rates were as follows: stage I, 77% (33/43); II, 56% (45/80); III, 42% (43/103); and IV, 14% (7/51) (chi2 = 40.62, P = 0.001). Survival estimates can be improved by adding carefully studied and suitably defined patient variables to the TNM system. The current TNM staging system for oral cavity cancer is based solely on the morphologic description of the tumor and disregards the clinical condition of the patient. Patient factors, such as cancer symptom severity and comorbidity, have a significant impact on survival. Continued exclusion of patient factors leads to imprecision in prognostic estimates and hinders interpretation of clinical studies.

Entities:  

Mesh:

Year:  1999        PMID: 9914547     DOI: 10.1016/S0194-5998(99)70367-0

Source DB:  PubMed          Journal:  Otolaryngol Head Neck Surg        ISSN: 0194-5998            Impact factor:   3.497


  16 in total

1.  Preclinical development of a bifunctional cancer cell homing, PKCepsilon inhibitory peptide for the treatment of head and neck cancer.

Authors:  Liwei Bao; Michael A Gorin; Manchao Zhang; Alejandra C Ventura; William C Pomerantz; Sofia D Merajver; Theodoros N Teknos; Anna K Mapp; Quintin Pan
Journal:  Cancer Res       Date:  2009-06-30       Impact factor: 12.701

2.  Development of a New Clinical Severity Staging System for Patients With Nonmetastatic Papillary Thyroid Carcinoma.

Authors:  Omar A Karadaghy; Dorina Kallogjeri; Jay F Piccirillo
Journal:  JAMA Otolaryngol Head Neck Surg       Date:  2017-12-01       Impact factor: 6.223

3.  Baseline health perceptions, dysphagia, and survival in patients with head and neck cancer.

Authors:  Miriam N Lango; Brian Egleston; Carolyn Fang; Barbara Burtness; Thomas Galloway; Jeffrey Liu; Ranee Mehra; Barbara Ebersole; Kathleen Moran; John A Ridge
Journal:  Cancer       Date:  2013-12-18       Impact factor: 6.860

4.  Prognostic impact of comorbidity in patients with bladder cancer.

Authors:  Ifeanyichukwu I Megwalu; Anna Vlahiotis; Mohamed Radwan; Jay F Piccirillo; Adam S Kibel
Journal:  Eur Urol       Date:  2007-11-05       Impact factor: 20.096

5.  Comparison of comorbidity collection methods.

Authors:  Dorina Kallogjeri; Sheila M Gaynor; Marilyn L Piccirillo; Raymond A Jean; Edward L Spitznagel; Jay F Piccirillo
Journal:  J Am Coll Surg       Date:  2014-03-19       Impact factor: 6.113

6.  Pretreatment health behaviors predict survival among patients with head and neck squamous cell carcinoma.

Authors:  Sonia A Duffy; David L Ronis; Scott McLean; Karen E Fowler; Stephen B Gruber; Gregory T Wolf; Jeffrey E Terrell
Journal:  J Clin Oncol       Date:  2009-03-16       Impact factor: 44.544

7.  High expressions of histone methylation- and phosphorylation-related proteins are associated with prognosis of oral squamous cell carcinoma in male population of Taiwan.

Authors:  Jen-Hao Chen; Kun-Tu Yeh; Yu-Min Yang; Jan-Gowth Chang; Huey-Er Lee; Shih-Ya Hung
Journal:  Med Oncol       Date:  2013-03-16       Impact factor: 3.064

8.  Association of Symptoms and Clinical Findings With Anticipated Outcomes in Patients With Recurrent Head and Neck Cancer.

Authors:  Patrik Pipkorn; Jordan Licata; Dorina Kallogjeri; Jay F Piccirillo
Journal:  JAMA Otolaryngol Head Neck Surg       Date:  2018-08-01       Impact factor: 6.223

9.  Outcome and fewer indications for adjuvant therapy for patients with oral squamous cell carcinomas under standardized tumor board conditions.

Authors:  Alexander Gröbe; Lena Rybak; Gerhard Schön; Ralf Smeets; Silke Tribius; Philippe Schafhausen; Till S Clauditz; Henning Hanken; Max Heiland
Journal:  J Cancer Res Clin Oncol       Date:  2015-10-27       Impact factor: 4.553

10.  Acute sensitivity of the oral mucosa to oncogenic K-ras.

Authors:  Louise van der Weyden; Maria P Alcolea; Philip H Jones; Alistair G Rust; Mark J Arends; David J Adams
Journal:  J Pathol       Date:  2011-03-07       Impact factor: 7.996

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.